Literature DB >> 14693596

Antagonism of cisatracurium and rocuronium block at a tactile train-of-four count of 2: should quantitative assessment of neuromuscular function be mandatory?

Aaron F Kopman1, Lee M Zank, Jennifer Ng, George G Neuman.   

Abstract

UNLABELLED: With a train-of-four (TOF) ratio >0.70 as the standard of acceptable recovery, postoperative residual paralysis is a frequent occurrence in postanesthesia care units (PACUs). However, detailed information regarding prior anesthetic management is rarely provided. We examined the incidence of postoperative weakness after the administration of cisatracurium and rocuronium when using a rigid protocol for muscle relaxant and subsequent neostigmine administration. Under desflurane, N(2)O, and opioid anesthesia, tracheal intubation was accomplished after either cisatracurium 0.15 mg/kg or rocuronium 0.60 mg/kg. The response of the thumb to ulnar nerve stimulation was estimated by palpation. Additional increments of muscle relaxant were given as needed to maintain the TOF count at 1 or 2. At the conclusion of surgery, at a TOF count of 2, neostigmine 0.05 mg/kg plus glycopyrrolate 10 micro g/kg was administered. The mechanical TOF response was then measured with a force transducer starting 5 min postreversal. Patients were observed until a TOF ratio of 0.90 was achieved. There were no significant differences in the recovery profiles of cisatracurium versus rocuronium. TOF ratios at 10 min postreversal were 0.72 +/- 0.10 and 0.76 +/- 0.11, respectively. At 15 min postreversal, only one subject in each group had a TOF ratio of <0.70. No patient in either group arrived in the PACU with a TOF ratio <0.70. Our results suggest that if cisatracurium or rocuronium is administered by using the TOF count as a guide, critical episodes of postoperative weakness in the PACU should be an infrequent occurrence. IMPLICATIONS: After the administration of cisatracurium or rocuronium, train-of-four (TOF) ratios <0.70 should rarely be observed in the postanesthesia care unit if neostigmine-assisted antagonism of residual block is delayed until the tactile TOF count at the thumb is 2 or more.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14693596     DOI: 10.1213/01.ane.0000094985.19305.e9

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  9 in total

1.  Comparison of Sugammadex versus Neostigmine Costs and Respiratory Complications in Patients with Obstructive Sleep Apnoea.

Authors:  Dilek Yazıcıoğlu Ünal; İlkay Baran; Murad Mutlu; Gülçin Ural; Taylan Akkaya; Onur Özlü
Journal:  Turk J Anaesthesiol Reanim       Date:  2015-12-01

2.  Comparative pharmacodynamics of pancuronium, cisatracurium, and CW002 in rabbits.

Authors:  Leslie L Diaz; Jingwei Zhang; Paul M Heerdt
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-05       Impact factor: 1.232

3.  Effect of isoflurane versus propofol-remifentanil anesthesia on neuromuscular blockade and hemodynamic responses by cisatracurium bolus injection.

Authors:  Dongho Hyun; Han-Bom Ryu; Mi-Woon Kim
Journal:  Korean J Anesthesiol       Date:  2011-10-22

4.  Use of neuromuscular blockers and neostigmine for general anesthesia and its association with neuraxial blockade: A retrospective study.

Authors:  Filipe Nadir Caparica Santos; Angélica de Fátima de Assunção Braga; Fernando Eduardo Feres Junqueira; Rafaela Menezes Bezerra; Felipe Ferreira de Almeida; Franklin Sarmento da Silva Braga; Vanessa Henriques Carvalho
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

5.  Use of sugammadex in clinical practice.

Authors:  Hee-Pyoung Park
Journal:  Korean J Anesthesiol       Date:  2017-07-13

6.  THYROID SURGERY, IONM AND SUGAMMADEX SODIUM RELATIONSHIPS: BENEFITS IN SUGAMMADEX SODIUM USE FOR IONM.

Authors:  T Donmez; V M Erdem; O Sunamak; H Ozcevik
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Oct-Dec       Impact factor: 0.877

Review 7.  Sugammadex: clinical development and practical use.

Authors:  Thomas Fuchs-Buder; Claude Meistelman; Julien Raft
Journal:  Korean J Anesthesiol       Date:  2013-12-26

Review 8.  Qualitative Neuromuscular Monitoring: How to Optimize the Use of a Peripheral Nerve Stimulator to Reduce the Risk of Residual Neuromuscular Blockade.

Authors:  Stephan R Thilen; Sanjay M Bhananker
Journal:  Curr Anesthesiol Rep       Date:  2016-03-22

9.  Effect of intraoperative neuromonitoring on efficacy and safety using sugammadex in thyroid surgery: randomized clinical trial.

Authors:  Mehmet Emin Gunes; Ahmet Cem Dural; Cevher Akarsu; Deniz Guzey; Nuri Alper Sahbaz; Evrim Kucur Tulubas; Sezer Bulut; Turgut Donmez
Journal:  Ann Surg Treat Res       Date:  2019-12-02       Impact factor: 1.859

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.